- Home
- THQ vs AVXL Comparison
THQ vs AVXL Comparison
Compare THQ & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THQ
- AVXL
- Stock Information
- Founded
- THQ 2014
- AVXL 2001
- Country
- THQ United States
- AVXL United States
- Employees
- THQ N/A
- AVXL N/A
- Industry
- THQ Finance Companies
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- THQ Finance
- AVXL Health Care
- Exchange
- THQ Nasdaq
- AVXL Nasdaq
- Market Cap
- THQ 845.7M
- AVXL 779.5M
- IPO Year
- THQ N/A
- AVXL N/A
- Fundamental
- Price
- THQ $20.76
- AVXL $8.35
- Analyst Decision
- THQ
- AVXL Strong Buy
- Analyst Count
- THQ 0
- AVXL 2
- Target Price
- THQ N/A
- AVXL $44.00
- AVG Volume (30 Days)
- THQ 158.9K
- AVXL 1.0M
- Earning Date
- THQ 01-01-0001
- AVXL 02-12-2025
- Dividend Yield
- THQ 7.53%
- AVXL N/A
- EPS Growth
- THQ N/A
- AVXL N/A
- EPS
- THQ N/A
- AVXL N/A
- Revenue
- THQ N/A
- AVXL N/A
- Revenue This Year
- THQ N/A
- AVXL N/A
- Revenue Next Year
- THQ N/A
- AVXL N/A
- P/E Ratio
- THQ N/A
- AVXL N/A
- Revenue Growth
- THQ N/A
- AVXL N/A
- 52 Week Low
- THQ $15.29
- AVXL $3.25
- 52 Week High
- THQ $20.38
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- THQ 56.80
- AVXL 40.39
- Support Level
- THQ $20.12
- AVXL $8.50
- Resistance Level
- THQ $21.00
- AVXL $9.20
- Average True Range (ATR)
- THQ 0.35
- AVXL 0.49
- MACD
- THQ -0.03
- AVXL -0.01
- Stochastic Oscillator
- THQ 62.14
- AVXL 32.23
About THQ abrdn Healthcare Opportunities Fund Shares of Beneficial Interest
abrdn Healthcare Opportunities Fund is a non-diversified closed-end fund in the United States. The fund's investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.